Slingshot members are tracking this event:

Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Phase 3 data is expected during the summer from Celgene regarding their ongoing REMARC studies for treating lymphoma with their blockbuster drug revlimid.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Occurred Source:
Related Keywords Lymphoma, Revlimid, Remarc Trial